Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
lerociclib + osimertinib
- Development stage
- Phase 2
- Lead developer
- G1 Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
Lerociclib (G1T38) + osimertinib (Tagrisso) is a combination therapy being investigated for EGFR mutation-positive non-small cell lung cancer (NSCLC). Lerociclib is an oral CDK4/6 inhibitor designed to stop cancer cell growth by inhibiting the enzymes CDK4 and CDK6, which are involved in cell cycle progression. Osimertinib is an irreversible EGFR tyrosine kinase inhibitor that blocks EGFR-sensitizing and EGFR T790M-resistance mutations. The combination aims to enhance efficacy and potentially overcome resistance mechanisms in patients who have progressed on first-line EGFR inhibitors.
- Other names
- lerociclib + Tagrisso
02
Targets
Beyond the preview
Go deeper on lerociclib + osimertinib.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on lerociclib + osimertinib.